Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00104429
Status:
TERMINATED
Last Update Posted:
2017-05-30
First Post:
2005-02-28
Brief Title:
GW873140 In Combination With Combivir In HIV Infected Subjects
Sponsor:
ViiV Healthcare
Organization:
ViiV Healthcare
Study Overview
Official Title:
A PhaseIIb 96 Week Randomised Partially Double-blinded Multicentre Parallel Group Repeat Dose Study to Evaluate the Safety Tolerability PK and Antiviral Effect of GW873140 in Combination With COMBIVIR Lamivudine and Zidovudine Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults
Status:
TERMINATED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected untreated subjects
Detailed Description:
A Phase IIb 96 week randomized partially double-blinded multicenter parallel group repeat dose study to evaluate the safety tolerability pharmacokinetics and antiviral effect of GW873140 in combination with Combivir lamivudine and zidovudine upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None